159 related articles for article (PubMed ID: 23856296)
1. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults.
Potter AS; Dunbar G; Mazzulla E; Hosford D; Newhouse PA
Biol Psychiatry; 2014 Feb; 75(3):207-14. PubMed ID: 23856296
[TBL] [Abstract][Full Text] [Related]
2. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study.
Wilens TE; Verlinden MH; Adler LA; Wozniak PJ; West SA
Biol Psychiatry; 2006 Jun; 59(11):1065-70. PubMed ID: 16499880
[TBL] [Abstract][Full Text] [Related]
3. A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder.
Bain EE; Apostol G; Sangal RB; Robieson WZ; McNeill DL; Abi-Saab WM; Saltarelli MD
J Clin Psychiatry; 2012 Jun; 73(6):783-9. PubMed ID: 22795204
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder.
Manor I; Ben-Hayun R; Aharon-Peretz J; Salomy D; Weizman A; Daniely Y; Megiddo D; Newcorn JH; Biederman J; Adler LA
J Clin Psychiatry; 2012 Dec; 73(12):1517-23. PubMed ID: 23290324
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled crossover study of α4β 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder.
Jucaite A; Öhd J; Potter AS; Jaeger J; Karlsson P; Hannesdottir K; Boström E; Newhouse PA; Paulsson B
Psychopharmacology (Berl); 2014 Mar; 231(6):1251-65. PubMed ID: 23640072
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study.
Apostol G; Abi-Saab W; Kratochvil CJ; Adler LA; Robieson WZ; Gault LM; Pritchett YL; Feifel D; Collins MA; Saltarelli MD
Psychopharmacology (Berl); 2012 Feb; 219(3):715-25. PubMed ID: 21748252
[TBL] [Abstract][Full Text] [Related]
8. A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment.
Dunbar GC; Kuchibhatla RV; Lee G;
J Psychopharmacol; 2011 Aug; 25(8):1020-9. PubMed ID: 20542923
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of metadoxine extended release in patients with predominantly inattentive subtype attention-deficit/hyperactivity disorder.
Manor I; Newcorn JH; Faraone SV; Adler LA
Postgrad Med; 2013 Jul; 125(4):181-90. PubMed ID: 23933905
[TBL] [Abstract][Full Text] [Related]
10. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
12. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
Rösler M; Retz W; Fischer R; Ose C; Alm B; Deckert J; Philipsen A; Herpertz S; Ammer R
World J Biol Psychiatry; 2010 Aug; 11(5):709-18. PubMed ID: 20353312
[TBL] [Abstract][Full Text] [Related]
13. Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder.
Potter AS; Newhouse PA
Pharmacol Biochem Behav; 2008 Feb; 88(4):407-17. PubMed ID: 18022679
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD.
Bain EE; Robieson W; Pritchett Y; Garimella T; Abi-Saab W; Apostol G; McGough JJ; Saltarelli MD
Neuropsychopharmacology; 2013 Feb; 38(3):405-13. PubMed ID: 23032073
[TBL] [Abstract][Full Text] [Related]
16. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
Fallu A; Richard C; Prinzo R; Binder C
Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
[TBL] [Abstract][Full Text] [Related]
17. Pozanicline for the treatment of attention-deficit/hyperactivity disorder.
Childress A; Sallee FR
Expert Opin Investig Drugs; 2014 Nov; 23(11):1585-93. PubMed ID: 25196198
[TBL] [Abstract][Full Text] [Related]
18. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
[TBL] [Abstract][Full Text] [Related]
19. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
Adler LA; Sutton VK; Moore RJ; Dietrich AP; Reimherr FW; Sangal RB; Saylor KE; Secnik K; Kelsey DK; Allen AJ
J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
